David Geffen School of Medicine

IN VITRO DIAGNOSTICS Castle Biosciences Inc. Castle Biosciences brings in $11.8mm through late-stage venture round Molecular diagnostics company Castle Biosciences Inc. raised $11.8mm through

Despite market headwinds, endovascular treatments for acute ischemic stroke (AIS) continue to represent a large, rapidly emerging market with a worldwide opportunity estimated at more than $1 billion.

Despite market headwinds, endovascular treatments for acute ischemic stroke (AIS) continue to represent a large, rapidly emerging market with a worldwide opportunity estimated at more than $1 billion.

FDA's effort to create a clearer path for antibiotic development has produced a series of new guidance documents that are making some drug candidates look well-positioned for regulatory review, and re